论文部分内容阅读
目的探讨左氧氟沙星联合其他抗痨方案治疗耐药肺结核(MDR-TB)的临床疗效以及安全性。方法将我院2008年10月到2010年12月收治的MDR-TB患者80例,随机分为对照组与治疗组,每组40例。对照组给予3DZETh/9DTh方案治疗;治疗组给予3DZEThV/9DThV方案治疗,疗程15个月。比较两组满疗程时的痰菌变化、病灶变化、空洞闭合情况及药物不良作用。结果治疗组治疗各个阶段痰菌阴转率均明显高于对照组;治疗组的病灶吸收率以及空洞闭合有效率均高于对照组;两组不良反应比较差异无统计学意义(P>0.05)。结论左氧氟沙星联合其他抗痨药物治疗MDR-TB有利于痰菌阴转和病变的吸收,临床疗效确切,不良反应小,值得推广应用。
Objective To investigate the clinical efficacy and safety of levofloxacin combined with other anti-tuberculosis drugs in the treatment of drug-resistant pulmonary tuberculosis (MDR-TB). Methods Eighty MDR-TB patients admitted to our hospital from October 2008 to December 2010 were randomly divided into control group and treatment group, 40 cases in each group. The control group was given 3DZETh / 9DTh regimen; the treatment group was treated with 3DZEThV / 9DThV regimen for 15 months. The two groups of sputum when the full course of treatment changes, changes in lesions, empty closure and adverse drug effects. Results The sputum negative conversion rate in the treatment group was significantly higher than that in the control group. The absorption rate of the lesion and the effective rate of void closure in the treatment group were higher than those in the control group. There was no significant difference in adverse reactions between the two groups (P> 0.05) . Conclusion Levofloxacin combined with other anti-tuberculosis drugs in the treatment of MDR-TB is conducive to the absorption of sputum Yin Yin and lesions, the exact clinical efficacy, adverse reactions, it is worth promoting the application.